contact

PD Dr. Markus Joerger

titel PD Dr. med. et phil. nat.

first name Markus

last name Joerger

street Wallisellenstr. 261

city 8050 Zürich

country Switzerland

phone number 076-559 1070

mobile number 076-559 1070

e-mail markus.joerger@kssg.ch

alt. email markus.joerger@gmail.com

2

research profile

academic status Oberarzt/Oberärztin

department I

faculty Onkologie/Hämatologie

fields of research - Pharmacokinetics and pharmacodynamics ofcancer drugs- Pharmacogenetics and predictive markers in solidcancer patients- Phase1- and translational trial designs

3

research profile

former positions May 1997 - April 1998 :Internal Medicine, Thusis, Switzerland (head: Dr.med. U.P.Veraguth)

May 1998 - May 1999 :Neurology, Valens, Switzerland (head: Prof. Dr.med.J.Kesselring)

June 1999 – May 2000:Internal Medicine, University Hospital Zuerich,Switzerland (head: Prof. Dr.med. F.Follath)

May 2000 – November 2001:Oncology, University Hospital Zuerich, Switzerland(head: Prof. Dr.med. Chr.Sauter) Clinical researchunter Prof. Dr.med. R.Stahel

November 2001 – July 2003:Internal Medicine and Oncology, Kantonsspital St.Gallen, Switzerland (head: Prof.Dr.med. R. Galeazzi(Internal Medicine), Prof. Dr.med. Th. Cerny(Oncology)

August 2003 – December 2007:Research fellow unter Prof. Dr. med. J. Schellensund Prof. J. Beijnen, Netherlands Cancer Institute,Amsterdam, The Netherlands

January 2004 – December 2006:Clinical expert for the Dutch Branch of theEuropean Medicines Evaluation Agency (EMEA)

4

research profile

January 2007 – June 2008:Department of Oncology and Hematology,Kantonsspital St.Gallen, Switzerland, under Prof.Th. Cerny.

July 2008 – July 2009:Senology Center of Eastern Switzerland,Kantonsspital St. Gallen, under Prof. B. Thürlimann

affiliations 1996 – present : Foederatio MedicorumHelveticorum2001 - present : European Society ofMedical Oncology2001 - present : American Association ofCancer Research2001 - present : American Society ofClinical Oncology2001 - present : Flims Alumni Club

5

research profile

awards Medical diploma : November 1996

MD: November 1996 “Basler Befragung vonDrogenabhängigen zur Medikamentengruppe derBenzodiazepine”

1-year fellowship from the "Union InternationalContre le Cancer" (UICC) 2002

1-year fellowship from the European Society ofMedical Oncology (ESMO) 2003

1-year fellowship from the Swiss NationalFoundation (SNF) 2003

FMH Internal Medicine : February 1, 2007

FMH Medical Oncology : April 29, 2008

PhD: December 18, 2007, Utrecht University,The Netherlands “Pharmacokinetic andpharmacogenetic profiling in solid cancer patients”

6

publications

title

journalpaper/review

Gachechiladze M, Škarda J, Kolek V, Grygárková I, Langová K, Bouchal J,Kolář Z, Baty F, Stahel R, Weder W, Soltermann A, Joerger M. Prognosticand predictive value of loss of nuclear RAD51 immunoreactivity inresected non-small cell lung cancer patients. Lung Cancer 2017;105:31-38.

Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-genevariation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. JTransl Med 2017; 15:66.

Joerger M, Finn S P, Cuffe S, Byrne A T, Gray S G. The IL-17-Th1/Th17pathway: an attractive target for lung cancer therapy?. Expert Opin TherTargets 2016; 20:1339-1356.

Klopp-Schulze L, Joerger M, Wicha S G, Parra-Guillen Z P, Kloft C. Makinguse of modeling and simulations: Towards individualized tamoxifentherapy in breast cancer. Int J Clin Pharmacol Ther 2016;.

Baty F, Joerger M, Früh M, Brutsche M. 61PD 24h-blood profile geneexpression biomarkers of the response to targeted therapy in advancednon-squamous non-small cell lung cancer (NSCLC). J Thorac Oncol 2016;11:S81.

Hager S, Ackermann C J, Joerger M, Gillessen S, Omlin A. Anti-tumouractivity of platinum compounds in advanced prostate cancer-a systematicliterature review. Ann Oncol 2016; 27:975-84.

Meulendijks D, Rozeman E A, Cats A, Sikorska K, Joerger M, Deenen M J,Beijnen J H, Schellens J H M. Pharmacogenetic variants associated withoutcome in patients with advanced gastric cancer treated withfluoropyrimidine and platinum-based triplet combinations: a pooledanalysis of three prospective studies. Pharmacogenomics J 2016;.

7

publications

title

journalpaper/review

Joerger M, von Pawel J, Kraff S, Fischer J R, Eberhardt W, Gauler T C,Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp H G,Behringer D M, Ko Y D, Hilger R A, Roessler M, Kloft C, Henrich A, MoritzB, Miller M C, Salamone S J, Jaehde U. Open-label, randomized study ofindividualized, pharmacokinetically (PK)-guided dosing of paclitaxelcombined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2016; 27:1895-902.

Crombag M R B S, Joerger M, Thürlimann B, Schellens J H M, Beijnen J H,Huitema A D R. Pharmacokinetics of Selected Anticancer Drugs in ElderlyCancer Patients: Focus on Breast Cancer. Cancers (Basel) 2016; 8:.

Hamzic S, Wenger N, Froehlich T K, Joerger M, Aebi S, Largiadèr C R,Amstutz U. The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics J 2016;.

Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, BrutscheM, Baty F, Krähenbühl S, cerny t, Joerger M. Erlotinib has comparableclinical efficacy to chemotherapy in pretreated patients with advancednon-small cell lung cancer (NSCLC): A propensity-adjusted, outcomesresearch-based study. Lung Cancer 2016; 100:38-44.

Warschkow R, Gueller U, tarantino i, cerny t, Schmied B, Thürlimann B,Joerger M. Improved Survival After Primary Tumor Surgery in MetastaticBreast Cancer: A Propensity-adjusted, Population-based SEER TrendAnalysis. Ann Surg 2016; 263:1188-98.

Warschkow R, cerny t, Schmied B, Gueller U, Thürlimann B, Joerger M. Apopulation-based analysis of secondary malignancies in breast cancerpatients receiving breast reconstruction. Br J Cancer 2016; 115:80-4.

8

publications

title

journalpaper/review

Shao S, Guo T, Gross V, Lazarev A, Koh C C, Gillessen Sommer S, JoergerM, Jochum W, Aebersold R. Reproducible Tissue Homogenization andProtein Extraction for Quantitative Proteomics Using MicroPestle-AssistedPressure-Cycling Technology. J Proteome Res 2016; 15:1821-9.

Kraff S, Nieuweboer A J M, Mathijssen R H J, Baty F, de Graan A J, vanSchaik R H N, Jaehde U, Joerger M. Pharmacokinetically based dosing ofweekly paclitaxel to reduce drug-related neurotoxicity based on a singlesample strategy. Cancer Chemother Pharmacol 2015;.

Joerger M, van Schaik R H N, Becker M L, Hayoz S, Pollak M, CathomasR, Winterhalder R, Gillessen Sommer S, Rothermundt C. Multidrug andtoxin extrusion 1 and human organic cation transporter 1 polymorphismsin patients with castration-resistant prostate cancer receiving metformin(SAKK 08/09). Prostate Cancer Prostatic Dis 2015;.

Shao S, Guo T, Koh C C, Gillessen Sommer S, Joerger M, Jochum W,Aebersold R. Minimal sample requirement for highly multiplexed proteinquantification in cell lines and tissues by PCT-SWATH mass spectrometry.Proteomics 2015; 15:3711-21.

Driessen C, Kraus M, Joerger M, Rosing H, Bader J, Hitz F, Berset C,Xyrafas A, Hawle H, Berthod G, Overkleeft H S, Sessa C, Huitema A,Pabst T, von Moos R, Hess D, Mey U J M. Treatment with the HIVprotease inhibitor nelfinavir triggers the unfolded protein response andmay overcome proteasome inhibitor resistance of multiple myeloma incombination with bortezomib: a phase I trial (SAKK 65/08).Haematologica 2015; 101:346-55.

9

publications

title

journalpaper/review

Guo T, Kouvonen P, Koh C C, Gillet L C, Wolski W E, Röst H L,Rosenberger G, Collins B C, Blum L C, Gillessen Sommer S, Joerger M,Jochum W, Aebersold R. Rapid mass spectrometric conversion of tissuebiopsy samples into permanent quantitative digital proteome maps. NatMed 2015; 21:407-13.

Joerger M, Huitema A D R, Boot H, Cats A, Doodeman V D, Smits P H M,Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, cerny t,Beijnen J H, Schellens J H M. Germline TYMS genotype is highlypredictive in patients with metastatic gastrointestinal malignanciesreceiving capecitabine-based chemotherapy. Cancer ChemotherPharmacol 2015; 75:763-72.

Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thürlimann B, cerny t. Off-label use of anticancerdrugs in eastern Switzerland: a population-based prospective cohortstudy. Eur J Clin Pharmacol 2014; 70:719-25.

Froehlich T K, Amstutz U, Aebi S, Joerger M, Largiadèr C R. Clinicalimportance of risk variants in the dihydropyrimidine dehydrogenase genefor the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer2014; 136:730-9.

Joerger M. Metabolism of the taxanes including nab-paclitaxel. ExpertOpin Drug Metab Toxicol 2014;1-12.

Joerger M, Baty F, Früh M, Droege C, Stahel R A, Betticher D C, von MoosR, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, KlingbielD, Zappa F, Brutsche M. Circulating microRNA profiling in patients withadvanced non-squamous NSCLC receiving bevacizumab/erlotinib followedby platinum-based chemotherapy at progression (SAKK 19/05). LungCancer 2014; 85:306-13.

10

publications

title

journalpaper/review

Früh M, Besrour H, Gillessen Sommer S, Joerger M, Hitz F, Savidan A,cerny t, Ess S. Management of elderly patients with advanced non-smallcell lung cancer: a single-center experience. Chemotherapy 2013;59:42-50.

Büchel B, Sistonen J, Joerger M, Aebi Y, Schürch S, Largiadèr C R.Comparative evaluation of the My5-FU™ immunoassay and LC-MS/MS inmonitoring the 5-fluorouracil plasma levels in cancer patients. Clin ChemLab Med 2013; 51:1681-8.

Joerger M, Thürlimann B. Chemotherapy regimens in early breast cancer:major controversies and future outlook. Expert Rev Anticancer Ther2013; 13:165-78.

Joerger M, Huitema A D R, Koeberle D, Rosing H, Beijnen J H, Hitz F,cerny t, Schellens J H M, Gillessen Sommer S. Safety and pharmacologyof gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol2013; 73:113-24.

Joerger M. [Role of individualized dosing in oncology: are we there yet?].Praxis (Bern 1994) 2013; 103:33-9.

Büchel B, Joerger M, Schürch S, Largiader C. Assessment of metabolic5,6-dihydourcail/uracil ratios as predictors of 5-fluorouracil-relatedtoxicities. 2012; Clinical Chemistry Annual Conference:.

Joerger M, Huober J. Diagnostic and prognostic use of bone turnovermarkers. Recent Results Cancer Res 2012; 192:197-223.

Joerger M, Ess S, Dehler S, Savidan A, Bouchardy C, Frick H, KonzelmannI, Thürlimann B. A population-based study on the patterns of use ofdifferent chemotherapy regimens in Swiss patients with early breastcancer. Swiss Med Wkly 2012; 142:w13571.

11

publications

title

journalpaper/review

hochstrasser a, Benz G, Joerger M, templeton a, Brutsche M, Früh M.Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?.Chemotherapy 2012; 58:84-88.

Büchel B, Joerger M, Schürch S, Largiader C. Characterization ofendogenous UH2/U metabolite ratios in cancer patients receiving 5-fluorouracil chemotherapy. Biomed Chromatogr 2012;.

Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B,Schwenkglenks M. Addition of cetuximab to first-line chemotherapy inpatients with advanced non-small-cell lung cancer: a cost-utility analysis.Ann Oncol 2012; 22:567-574.

Joerger M. Covariate pharmacokinetic model building in oncology and itspotential clinical relevance. AAPS J 2012; 14:119-32.

Joerger M, Kraff S, Huitema A D R, Feiss G, Moritz B, Schellens J H M,Beijnen J H, Jaehde U. Evaluation of a pharmacology-driven dosingalgorithm of 3-weekly paclitaxel using therapeutic drug monitoring: apharmacokinetic-pharmacodynamic simulation study. Clin Pharmacokinet2012; 51:607-17.

Joerger M, Huitema A D R, Illerhaus G, Ferreri A J M. Rationaladministration schedule for high-dose methotrexate in patients withprimary central nervous system lymphoma. Leuk Lymphoma 2012;53:1867-75.

Joerger M, Thürlimann B, Savidan A, Frick H, Rageth C, Lütolf U, VlastosG, Bouchardy C, Konzelmann I, Bordoni A, Probst-Hensch N, Jundt G, EssS. Treatment of breast cancer in the elderly: a prospective, population-based Swiss study. J Geriatr Oncol 2012; 4:39-47.

Joerger M, Matter-Walstra K, Früh M. Addition of cetuximab to first-linechemotherapy in patients with advanced non-small-cell lung cancer: acost–utility analysis. Ann Oncol 2012; 22:567-574.

12

publications

title

journalpaper/review

Joerger M, Ferreri A J M, Krähenbühl S, Schellens J H M, cerny t, Zucca E,Huitema A D R. Dosing algorithm to target a predefined AUC in patientswith primary central nervous system lymphoma receiving high dosemethotrexate. Br J Clin Pharmacol 2012; 73:240-7.

Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, KonzelmannI, Probst-Hensch N, Ess S. A population-based study on theimplementation of treatment recommendations for chemotherapy in earlybreast cancer. Clin Breast Cancer 2012; 12:102-9.

Joerger M, Wilkins J, Fagagnini S, Baldinger R, Brenneisen R, SchneiderU, Goldman B, Weber M. Single-dose pharmacokinetics and tolerability oforal delta-9- tetrahydrocannabinol in patients with amyotrophic lateralsclerosis. Drug Metab Lett 2012; 6:102-8.

Joerger M, deJong D, Burylo A, Burgers J A, Baas P, Huitema A D R,Beijnen J H, Schellens J H M. Tubulin, BRCA1, ERCC1, Abraxas, RAP80mRNA expression, p53/p21 immunohistochemistry and clinical outcomein patients with advanced non small-cell lung cancer receiving first-lineplatinum-gemcitabine chemotherapy. Lung Cancer 2011; 74:310-7.

adamina m, Joerger M. Dose-toxicity models in oncology. Expert OpinDrug Metab Toxicol 2011; 7:201-211.

Joerger M. Dose-toxicity models in oncology. Expert Opin Drug MetabToxicol 2011; 7:201-11.

Joerger M, Huitema A D R, Illerhaus G, Ferreri A J M. High-dosemethotrexate in patients with primary central nervous systemlymphoma: does drug exposure really matter?. Leuk Lymphoma 2011;52:1825-7.

13

publications

title

journalpaper/review

Joerger M, Thürlimann B, Savidan A, Frick H, Bouchardy C, KonzelmannI, Probst-Hensch N, Ess S. A Population-Based Study on theImplementation of Treatment Recommendations for Chemotherapy inEarly Breast Cancer. Clin Breast Cancer 2011;.

Joerger M, Burgers S A, Baas P, Smit E F, Haitjema T J, Bard M P L,Doodeman V D, Smits P H M, Vincent A, Huitema A D R, Beijnen J H,Schellens J H M. Germline polymorphisms in patients with advancednonsmall cell lung cancer receiving first-line platinum-gemcitabinechemotherapy: a prospective clinical study. Cancer 2011; 118:2466-75.

Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B,Schwenkglenks M. Cost-effectiveness of maintenance pemetrexed inpatients with advanced nonsquamous-cell lung cancer from theperspective of the Swiss health care system. Value Health 2011;15:65-71.

Joerger M, Burgers J A, Baas P, Doodeman V D, Smits P H M, Jansen R S,Vainchtein L D, Rosing H, Huitema A D R, Beijnen J H, Schellens J H M.Gene polymorphisms, pharmacokinetics, and hematological toxicity inadvanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2011; 69:25-33.

Joerger M, Riesen W F, Thürlimann B. Bevacizumab-associatedhyperlipoproteinemia type IIb in a patient with advanced invasive-ductalbreast cancer. J Oncol Pharm Pract 2010;.

Buikhuisen W A, Burgers J A, Vincent A D, Schellens J H M, Beijnen J H,Smit E F, Joerger M. Pemetrexed pathway-associated germlinepolymorphisms: a useful tool for treatment individualization?. J ClinOncol 2010; 28:e482-3; author reply e484.

14

publications

title

journalpaper/review

Joerger M, Omlin A, cerny t, Früh M. The role of pemetrexed in advancednon small-cell lung cancer: special focus on pharmacology andmechanism of action. Current drug targets 2010; 11:37-47.

Joerger M, templeton a, koeberle d, Engler H, Riesen W F, Thürlimann B.Procollagen type I N-propeptide is a predictor of skeletal morbidity inpatients with malignant osteolytic bone disease on bisphosphonates.Cancer Chemother Pharmacol 2010;.

Joerger M, Thürlimann B, huober j. Small HER2-positive, node-negativebreast cancer: who should receive systemic adjuvant treatment?. AnnOncol 2010; 22:17-23.

Ess S, Joerger M, Frick H, Probst-Hensch N, Vlastos G, Rageth C, LütolfU, Savidan A, Thürlimann B. Predictors of state-of-the-art managementof early breast cancer in Switzerland. Ann Oncol 2010; 22:618-24.

Joerger M, Huitema A D R, Krähenbühl S, Schellens J H M, cerny t, ReniM, Zucca E, Cavalli F, Ferreri A J M. Methotrexate area under the curve isan important outcome predictor in patients with primary CNS lymphoma:A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20trial. Br J Cancer 2010; 102:673-7.

Joerger M. Cancer chemotherapy: targeting folic acid synthesis. CancerManag Res 2010; 2:293-301.

Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B,Schwenkglenks M. Addition of cetuximab to first-line chemotherapy inpatients with advanced non-small-cell lung cancer: a cost-utility analysis.Ann Oncol 2010; 22:567-74.

15

publications

title

journalpaper/review

Smit E F, Burgers S A, Biesma B, Smit H J M, Eppinga P, Dingemans A MC, Joerger M, Schellens J H, Vincent A, van Zandwijk N, Groen H J M.Randomized phase II and pharmacogenetic study of pemetrexedcompared with pemetrexed plus carboplatin in pretreated patients withadvanced non-small-cell lung cancer. Journal of clinical oncology : officialjournal of the American Society of Clinical Oncology 2009; 27:2038-45.

templeton a, Thürlimann B, Joerger M. Ixabepilon bei lokalfortgeschrittenem oder metastasiertem Mammakarzinom: NeueBehandlungsoptionen nach Taxanen und Anthrazyklinen. SchweizerKrebsbulletin 2009;114-117.

Joerger M. Neue Optionen endokriner Therapieindividualisierung?Pharmakogenetik bei Brustkrebs: Leading Opinions. Medizin für die Frau2009; 1:28-30.

Joerger M, Senn H J, Thürlimann B. St. Gallen 2009 recommendations onthe treatment of early breast cancer: consensus and controversy.magazine of european medical oncology 2009; 2:229-231.

Joerger M, Thürlimann B. Update of the BIG 1-98 Trial: where do westand?. Breast 2009; 18 Suppl 3:S78-82.

Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic Drugs inOncology: A Focus on Drug Safety and the Elderly - A Mini-Review.Gerontology 2009;.

Ribi K, Bernhard J, Schuller J C, Weder W, Bodis S, Joerger M, BetticherD, Schmid R A, Stupp R, Ris H B, Stahel R A, Swiss Group for ClinicalCancer Research SAKK . Individual versus standard quality of lifeassessment in a phase II clinical trial in mesothelioma patients: feasibilityand responsiveness to clinical changes. Lung cancer (Amsterdam,Netherlands) 2008; 61:398-404.

16

publications

title

journalpaper/review

Joerger M, nuessli d, Henz S, Zaunbauer W, cerny t, Cogliatti S B,Gillessen Sommer S. CT-diagnosed mesenteric alterations in patients withnon-Hodgkin's lymphoma: a population-based study. Onkologie 2008;31:514-9.

Joerger M, Huitema A D R, Richel D J, Dittrich C, Pavlidis N, Briasoulis E,Vermorken J B, Strocchi E, Martoni A, Sorio R, Sleeboom H P, Izquierdo MA, Jodrell D I, Calvert H, Boddy A V, Hollema H, Féty R, Van der Vijgh W JF, Hempel G, Chatelut E, Karlsson M, Wilkins J, Tranchand B, Schrijvers AH G J, Twelves C, Beijnen J H, Schellens J H M. Populationpharmacokinetics and pharmacodynamics of paclitaxel and carboplatin inovarian cancer patients: a study by the European organization forresearch and treatment of cancer-pharmacology and molecularmechanisms group and new drug development group. Clinical cancerresearch : an official journal of the American Association for CancerResearch 2007; 13:6410-8.

Joerger M, Huitema A D R, Richel D J, Dittrich C, Pavlidis N, Briasoulis E,Vermorken J B, Strocchi E, Martoni A, Sorio R, Sleeboom H P, Izquierdo MA, Jodrell D I, Féty R, de Bruijn E, Hempel G, Karlsson M, Tranchand B,Schrijvers A H G J, Twelves C, Beijnen J H, Schellens J H M, EORTC-PAMM-NDDG . Population pharmacokinetics and pharmacodynamics ofdoxorubicin and cyclophosphamide in breast cancer patients: a study bythe EORTC-PAMM-NDDG. Clinical pharmacokinetics 2007; 46:1051-68.

von Rohr L, Klaeser B, Joerger M, Kluckert T, cerny t, Gillessen SommerS. Increased pulmonary FDG uptake in bleomycin-associatedpneumonitis. Onkologie 2007; 30:320-3.

17

publications

title

journalpaper/review

Joerger M, Huitema A D R, Huizing M T, Willemse P H B, de Graeff A,Rosing H, Schellens J H M, Beijnen J H, Vermorken J B. Safety andpharmacology of paclitaxel in patients with impaired liver function: apopulation pharmacokinetic-pharmacodynamic study. British journal ofclinical pharmacology 2007; 64:622-33.

Joerger M, Kuhn M. Probleme langwirkender Betamimetika bei Asthma.Pharma-Kritik 2007; 29:.

Rohr L, Klaeser B, Joerger M, Kluckert J T, cerny t, Gillessen Sommer S.Increased pulmonary FDG Uptake in Bleomycin-associated pneumonitis.Onkologie 2007;320-323.

Greuter S, Joerger M, koeberle d. Adjuvante Therapie desKolonkarzinoms. Onkologie 2007; 3:20-24.

Joerger M, Huitema A D R, van den Bongard H J G D, Baas P, SchornagelJ H, Schellens J H M, Beijnen J H. Determinants of the elimination ofmethotrexate and 7-hydroxy-methotrexate following high-dose infusionaltherapy to cancer patients. British journal of clinical pharmacology 2006;62:71-80.

Jermann M, Stahel R A, Salzberg M, cerny t, Joerger M, GillessenSommer S, Morant R, Egli F, Rhyner K, Bauer J A, Pless M. A phase II,open-label study of gefitinib (IRESSA) in patients with locally advanced,metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy andpharmacology 2006; 57:533-9.

Joerger M, Huitema A D R, Boogerd W, van der Sande J J, Schellens J HM, Beijnen J H. Interactions of serum albumin, valproic acid andcarbamazepine with the pharmacokinetics of phenytoin in cancerpatients. Basic & clinical pharmacology & toxicology 2006; 99:133-40.

18

publications

title

journalpaper/review

Joerger M, Huitema A D R, van den Bongard D H J G, Schellens J H M,Beijnen J H. Quantitative effect of gender, age, liver function, and bodysize on the population pharmacokinetics of Paclitaxel in patients withsolid tumors. Clinical cancer research : an official journal of the AmericanAssociation for Cancer Research 2006; 12:2150-7.

Brouwers E E M, Tibben M M, Rosing H, Hillebrand M J X, Joerger M,Schellens J H M, Beijnen J H. Sensitive inductively coupled plasma massspectrometry assay for the determination of platinum originating fromcisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.Journal of mass spectrometry : JMS 2006; 41:1186-94.

Sparidans R W, Bosch T M, Joerger M, Schellens J H M, Beijnen J H.Liquid chromatography-tandem mass spectrometric assay for the analysisof uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for themeasurement of the activities of the pyrimidine catabolic enzymes.Journal of chromatography. B, Analytical technologies in the biomedicaland life sciences 2006; 839:45-53.

Joerger M, Bosch T M, Doodeman V D, Beijnen J H, Smits P H M,Schellens J H M. Novel deoxycytidine kinase gene polymorphisms: apopulation screening study in Caucasian healthy volunteers. Europeanjournal of clinical pharmacology 2006; 62:681-4.

Joerger M, koeberle d, Neumann H P H, Gillessen Sommer S. Von Hippel-Lindau disease--a rare disease important to recognize. Onkologie 2005;28:159-63.

Wuermli L, Joerger M, Henz S, Schmid H P, Riesen W F, Thomas G, KrekW, cerny t, Gillessen Sommer S. Hypertriglyceridemia as a possible riskfactor for prostate cancer. Prostate cancer and prostatic diseases 2005;8:316-20.

19

publications

title

journalpaper/review

Joerger M, Huitema A D R, Meenhorst P L, Schellens J H M, Beijnen J H.Pharmacokinetics of low-dose doxorubicin and metabolites in patientswith AIDS-related Kaposi sarcoma. Cancer chemotherapy andpharmacology 2005; 55:488-96.

Brouwers E E M, Tibben M M, Joerger M, van Tellingen O, Rosing H,Schellens J H M, Beijnen J H. Determination of oxaliplatin in humanplasma and plasma ultrafiltrate by graphite-furnace atomic-absorptionspectrometry. Analytical and bioanalytical chemistry 2005; 382:1484-90.

Diethelm M, Joerger M. Letale Polypharmazie bei einem Hypertoniker -Erwiderung. Deutsche medizinische Wochenschrift (1946) 2005;130:413-414.

Würmli L, Joerger M, Henz S, Schmid H P, Riesen W F, Thomas G, Krek W,cerny t, Gillessen Sommer S. Hypertriglyceridemia as a possible riskfactor for prostate cancer. Prostate Cancer Prostatic Dis 2005;8:316-320.

Dedes K J, Szucs T D, Bodis S, Joerger M, Lowy A, Russi E W, Steinert HC, Weder W, Stahel R A. Management and costs of treating lung cancerpatients in a university hospital. PharmacoEconomics 2004; 22:435-44.

Joerger M, Warzinek T, Klaeser B, Kluckert J T, Schmid H P, GillessenSommer S. Major tumor regression after paclitaxel and carboplatinpolychemotherapy in a patient with advanced penile cancer. Urology2004; 63:778-80.

20

publications

title

journalpaper/review

Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chassé E,Ratschiller D, Weder W, Joerger M, Betticher D C, Stahel R A, Ziegler A.Circulating deoxyribonucleic Acid as prognostic marker in non-small-celllung cancer patients undergoing chemotherapy. Journal of clinicaloncology : official journal of the American Society of Clinical Oncology2004; 22:4157-64.

Joerger M, Schellens J H M, Beijnen J H. Therapeutic drug monitoring ofnon-anticancer drugs in cancer patients. Methods and findings inexperimental and clinical pharmacology 2004; 26:531-45.

Joerger M, Warzinek T, Klaeser B, Kluckert J T, Schmid H P, GillessenSommer S. Major tumor regression afrer paclitaxel and carboplatinpolychemotherapy in a patient with advanced penile cancer. Urology2004; 63:778-780.

Joerger M, Diethelm M. Letale Polypharmazie bei einem Hypertoniker:Lethal polypharmacy in a patient with arterial hypertension. Deutschemedizinische Wochenschrift (1946) 2004; 129:2714-6.

Joerger M, Öhlschlegel C, cerny t, Gillessen Sommer S. Postradiationhigh-grade myofibroblastic sarcoma of the prostate -- a rare entity ofprostatic tumors -- responding to liposomal Doxorubicin. Onkologie 2002;25:558-61.

Joerger M, Gunz A, Speich R, Pestalozzi B C. Gemcitabine-relatedpulmonary toxicity. Swiss medical weekly : official journal of the SwissSociety of Infectious Diseases, the Swiss Society of Internal Medicine, theSwiss Society of Pneumology 2002; 132:17-20.

Walter R B, Joerger M, Pestalozzi B C. Gemcitabine-associated hemolytic-uremic syndrome. American journal of kidney diseases : the officialjournal of the National Kidney Foundation 2002; 40:E16.

21

publications

title

journalpaper/review

Joerger M, Beer S, Kesselring J. Impact of neurorehabilitation ondisability in patients with acutely and chronically disabling diseases of thenervous system measured by the Extended Barthel Index.Neurorehabilitation and neural repair 2001; 15:15-22.

Joerger M, Kuhn M, Hartmann K. Entzugssymptome der modernenAntidepressiva. Schweizerische Aerztezeitung 2001; 83:.

bookchapter

Joerger M, Hartmann K, & Kuhn M (2009). Side Effects of Drugs Annual31: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual31 (pp. 309). Oxford UK: Elsevier; Linacre House Jordan Hill.

Joerger M, Hartmann K, & Kuhn M (2008). Side Effects of Drugs Annual30: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual30. Oxford UK: Elsevier; Linacre House Jordan Hill.

Joerger M, Hartmann K, & Kuhn M (2005). Side Effects of Durgs Annual28: Drugs acting on the respiratory tract. In Side Effects of Durgs Annual28. Oxford UK: Elsevier; Linacre House Jordan Hill.

Joerger M, Hartmann K, & Kuhn M (2005). Side Effects of Drugs Annual29: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual29. Oxford UK: Elsevier; Linacre House Jordan Hill.

Pestalozzi B, & Joerger M (2003). Malignant liver tumors: Current andemerging therapies: Systematic treatment of hepatobiliary tumors. InMalignant liver tumors: Current and emerging therapies (pp. 91-99):Jones and Bartlett Publishers.

Kuhn M, Joerger M, & Hartmann K (2003). Side Effects of Drugs Annual26: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual26. Oxford UK: Elsevier; Linacre House Jordan Hill.

Pestalozzi B, & Joerger M (2002). Oncologic Emergencies: Drug relatedemergencies. In Oncologic Emergencies: Oxford University Press.

22

publications

title

bookchapter

Kuhn M, Joerger M, & Hartmann K (2001). Side Effects of Drugs Annual24: Drugs acting on the respiratory tract. In Side Effects of Drugs Annual24. Oxoford UK: Elsevier; Linacre House Jordan Hill.

conferencepaper/poster

Neumair P, Joos L, Warschkow R, Ess S, Hitz F, Früh M, Brutsche M, BatyF, Krähenbühl S, & Joerger M (2016). Chemotherapy is not superior toerlotinib in pretreated patients with advanced non-small cell lung cancer(NSCLC): A retrospective study: Abstrakt 169P. In J Thorac Oncol. 11(4Suppl) (pp. 131): Elsevier.

23

projects

title status

A Phase 2, multi-center, open label study of NIR178 incombination with PDR001 in patients with selected ad-vancedsolid tumors and non-Hodgkin lymphoma

ongoing-recruitingphase

SAKK 41/16: Neoadjuvant treatment with Regorafenib andCapecitabine combined with radiotherapy in locally advancedrectal ca cer. A multicenter phase Ib trial (RECAP)

ongoing-recruitingphase

PhenoTox: Hunting the missing heritability of early-onsetfluoropyrimdine-related toxicity in cancer patients: anobservational multi-center study

ongoing-recruitingphase

An open-label Phase 1/2a study of BAL101553 adminis-tered as48-hour intravenous infusions in adult patients with advancedsolid tumors

ongoing-recruitingphase

24

projects

title status

A Phase 1/2a Dose Escalation and Cohort Expansion Study forSafety, Tolerability, and Efficacy of BMS-986156 AdministeredAlone and in Combination with Nivolumab (BMS-936558, antiPD-1 Monoclonal Anti-body) in Advanced Solid Tumors

automat-icallyclosed

Predictive and prognostic value of integrated exon-levelexpression to approach drug-response and resistance to EGFR-targeted treatment in non-small cell lung cancer

automat-icallyclosed

25

projects

title status

MP0250; A phase I multi-centre, open-label, repeated-dose,dose-escalation study to assess safety, tolerability andpharmacokinetics of MP0250 in patients with advanced solidtumours

automat-icallyclosed

Cachexia and Toxicity: cachexia-based dosing vs. standard ofcare (CAT-Trial)

automat-icallyclosed

A Phase Ib/II, open-label, multicenter study of INC280 incombination with buparlisib in adult patients with recurrentglioblastoma

automat-icallyclosed

A phase III, multicenter, randomized, open-label study of oralLDK378 versus standard chemotherapy in adult patients withALK-rearranged (ALK-positive) advanced non-small cell lungcancer who have been treated previously with chemotherapy(platinum doublet) and crizotinib

automat-icallyclosed

26

projects

title status

LDE225 in combination with Paclitaxel in patients withadvanced solid tumors. A multicenter phase I trial

automat-icallyclosed

Pharmacogenetics and therapeutic drug monitoring for theoptimization of fluoropyrimidine treatment in patients withadvanced colorectal cancer (FLOXTOX II)

automat-icallyclosed

27

projects

title status

Circulating micro-RNA profiling in patients with advanced non-squamous non small-cell lung cancer receiving bevacizumab/erlotinib first-line treatment followed by platinum-basedchemotherapy at disease progression (SAKK 19/05)

completed

Serum and tissue biomarkers in patients with early andadvanced-stage renal-cell carcinoma

automat-icallyclosed

Cytochrom p450 3A4 and 1A2 phenotyping for theindividualization of treatment with sunitinib or erlotinib incancer patients

automat-icallyclosed

ETOP 2-11 (BELIEF) An open-label phase II trial of erlotinib andbevacizumab in pa-tients with advanced non-small cell lungcancer and activating EGFR mutations

ongoing- followup

28

projects

title status

A randomized, double-blind, placebo-controlled multi-centerstudy of BYM338 for treatment of cachexia in patients withstage IV non-small cell lung cancer or stage III/IVadenocarcinoma of the pancreas - EKSG 11/084

completed

29

projects

title status

Swiss Cyptam-2 - Clinical activity of tamoxifen inpostmenopausal patients with locally advanced or metastaticER-positive breast cancer by endoxifen concentrations andpharmacogenetics

completed

An open-label, randomized, parallel group study of patientstreated with Paclitaxel with standard dosing versuspharmacokinetic guided dose adjustment in patients withadvanced NSCLC

completed

30

projects

title status

A phase Ib multi-center, open label, 2-arm dose-escalationstudy of oral BEZ235 and BKM120 in combination with weeklypacli-taxel and trastuzumab in patients with advanced solidtumors

completed

Clinical activity of tamoxifen in postmenopausal patients withlocally advanced or metastatic ER-positive breast cancer byendoxifen concentrations and pharmacogenetics

completed

31

projects

title status

International, multicenter, open-label, phase II study toinvestigate the efficacy and safety of multiple doses ofIMAB362 in patients with advanced adenocarcinoma of thestomach or the lower esophagus

completed

Pleural pharmacokinetics of moxifloxacin and amoxicillin-clavulanate in the context of parapneumonic pleural effusionsand empyema

completed

First in human clinical development of the MC4 receptorantagonist scFv 1E8a (Obexia) - MFZ 2010_012

aborted

FLOxTox: Assessment of the Polygenic Basis of AdverseReactions to 5-Flourouracil/Leucovorin/Oxaliplatin of ColorectalCancer Patients Using a Pathway Approach

completed